Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;47(7):2358-61.
doi: 10.1128/AAC.47.7.2358-2361.2003.

Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline

Jutta Wagner  1 , Miriam Jabbusch, Martin Eisenblätter, Helmut Hahn, Constanze Wendt, Ralf Ignatius
Affiliations

Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline

Jutta Wagner et al. Antimicrob Agents Chemother. 2003 Jul.

Abstract

To elucidate Campylobacter jejuni resistance to antibiotics in Germany, MICs of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline were determined (using agar dilution) for 144 clinical isolates. The data indicate a considerable ciprofloxacin resistance (45.1%) without a clonal relationship of the strains and a greater in vitro activity of moxifloxacin, erythromycin, and clindamycin.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Cumulative MICs of ciprofloxacin (A), moxifloxacin (B), erythromycin (C), clindamycin (D), and tetracycline (E) for 144 C. jejuni isolates from human stool samples. R, breakpoint for resistance (not yet defined for moxifloxacin); %, percentage of isolates tested.
FIG. 1.
FIG. 1.
Cumulative MICs of ciprofloxacin (A), moxifloxacin (B), erythromycin (C), clindamycin (D), and tetracycline (E) for 144 C. jejuni isolates from human stool samples. R, breakpoint for resistance (not yet defined for moxifloxacin); %, percentage of isolates tested.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adler-Mosca, H., J. Luthy-Hottenstein, G. Martinetti Lucchini, A. Burnens, and M. Altwegg. 1991. Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10:953-957. - PubMed
    1. Atanassova, V., and C. Ring. 1999. Prevalence of Campylobacter spp. in poultry and poultry meat in Germany. Int. J. Food Microbiol. 51:187-190. - PubMed
    1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651. - PubMed
    1. Bebear, C. M., H. Renaudin, A. Boudjadja, and C. Bebear. 1998. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob. Agents Chemother. 42:703-704. - PMC - PubMed
    1. Chatzipanagiotou, S., E. Papavasileiou, A. Lakumenta, A. Makri, C. Nicolaou, K. Chantzis, S. Manganas, and N. I. Legakis. 2002. Antimicrobial susceptibility patterns of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. J. Antimicrob. Chemother. 49:803-805. - PubMed

Publication types

LinkOut - more resources